权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel roles of RNA modifications in the pathogenesis of pulmonary vascular remodeling and PAH

RNA修饰在肺血管重塑和PAH发病机制中的新作用

基本信息

批准号：
10540134
负责人：
YOU-YANG ZHAO
金额：
$ 68万
依托单位：
LURIE CHILDREN'S HOSPITAL OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10540134
关键词：
Address Adenosine Adult Affect Animal Model Area Arginine CRISPR/Cas technology CXCL12 gene Cessation of life Chronic Clinical Clustered Regularly Interspaced Short Palindromic Repeats Coupled Data Dioxygenases Disease Endothelial Cells Endothelium Epigenetic Process FDA approved Fatty acid glycerol esters Functional disorder Gene Expression Gene Transfer Genes Goals Human Hypoxia Impairment Interleukin-6 Knockout Mice Link Lung Malignant Neoplasms Meclofenamic Acid Mediating Messenger RNA Metabolism Modeling Modification Molecular Monocrotaline Morbidity - disease rate Mus Nitric Oxide Obesity PDGFB gene Pathogenesis Patients Pharmaceutical Preparations Pharmacology Phenotype Platelet-Derived Growth Factor Post-Transcriptional Regulation Prevention Proteins Protocols documentation Pulmonary Vascular Resistance RNA RNA Stability RNA metabolism Rattus Regulation Regulator Genes Research Role S-Adenosylhomocysteine Site Stimulus Structure of parenchyma of lung Therapeutic Therapeutic Agents Therapeutic Effect Time Transcription Coactivator Translations Vascular Endothelial Cell Vascular remodeling alpha ketoglutarate arginase base bioprocess clinically relevant demethylation druggable target effective therapy endothelial dysfunction human disease in vivo inhibitor insight mRNA Stability methyl group mortality mutant nanoparticle new therapeutic target next generation sequencing novel novel therapeutic intervention novel therapeutics premature primary pulmonary hypertension pulmonary arterial hypertension pulmonary vascular remodeling pulmonary vasoconstriction resistance gene response right ventricular failure synergism therapeutic evaluation transcription factor translational potential vasoconstriction

项目摘要

Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and obliterative vascular remodeling that causes right heart failure and premature death. Given the underlying molecular mechanisms of obliterative vascular remodeling remain enigmatic, current therapies have not targeted the fundamental disease modifying mechanisms and hence only resulted in a modest improvement in the morbidity and mortality. While several transcription factors and transcriptional co- activators have been studied in the context of PAH, post-transcriptional regulations of mRNAs that can affect expression of key proteins remain largely unexplored. RNA modifications including N6-methyladenosine (m6A) have recently been discovered as essential regulators of gene expression. The m6A modification controls RNA stability, transport, and translation and has been linked to human diseases such as obesity and cancers. Despite its functional importance in various fundamental bioprocesses, studies of m6A modification of mRNAs in PAH are lacking. Our Supporting Data show that expression of fat mass and obesity-associated protein (FTO), a well-characterized RNA demethylase, is markedly elevated in pulmonary vascular endothelial cells (ECs) of idiopathic PAH patients. Tie2Cre-mediated deletion of Fto in ECs (FtoTie2Cre) inhibited PH induced by chronic hypoxia. Our mechanistic studies provide evidence that several PAH-causing genes are potential FTO targets in human lung ECs. Furthermore, pharmacological inhibition of FTO in monocrotaline- challenged rats inhibited pulmonary vascular remodeling and PH. Thus, we hypothesize that endothelial FTO, as a major m6A eraser, acts as a key regulator of mRNA stability and accumulation of key PAH-causing genes in ECs to regulate pulmonary vasoconstriction and vascular remodeling and thus is a novel therapeutic target for PAH. We propose the following 3 Specific Aims. In Aim 1, we will define the fundamental role of endothelial FTO in the pathogenesis of PAH. In Aim 2, we will delineate the molecular mechanisms underlying FTO regulation of endothelial dysfunction leading to pulmonary vasoconstriction and vascular remodeling. We will identify the key FTO targets in ECs and address the possibility of rescuing the phenotype of FtoTieCre by novel nanoparticle-mediated in vivo EC-specific gene transfer. In Aim 3, we will explore the therapeutic potential of FTO inhibitors including a repurposed FDA-approved drug in the treatment of PAH employing 3 complimentary animal models of PAH. Based on the clear clinical relevance of our novel findings, we expect that the proposed studies have significant translational potential by delineating the molecular and cellular mechanisms of endothelial dysfunction leading to pulmonary vasoconstriction and vascular remodeling, identifying druggable targets, and exploring pharmacological agents that can pharmacologically inhibit/reverse vascular remodeling and also inhibit vasoconstriction for the prevention and treatment of PAH in patients. Thus, we believe the proposed studies have great translational potential.

肺动脉高压（PAH）以肺血管进行性增高为特征